2026-02-09 04:16:06
As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.
2025-10-19 11:44:20